Cargando…

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects

Although B cell depletion is an effective therapy of multiple sclerosis (MS), the pathogenic functions of B cells in MS remain incompletely understood. We asked whether cerebrospinal fluid (CSF) B cells in MS secrete different cytokines than control-subject B cells and whether cytokine secretion aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Jason, Xu, Quangang, Jackson, Kayla C., Romm, Elena, Wuest, Simone C., Kosa, Peter, Wu, Tianxia, Bielekova, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062589/
https://www.ncbi.nlm.nih.gov/pubmed/30079049
http://dx.doi.org/10.3389/fneur.2018.00554
_version_ 1783342401671135232
author Stein, Jason
Xu, Quangang
Jackson, Kayla C.
Romm, Elena
Wuest, Simone C.
Kosa, Peter
Wu, Tianxia
Bielekova, Bibiana
author_facet Stein, Jason
Xu, Quangang
Jackson, Kayla C.
Romm, Elena
Wuest, Simone C.
Kosa, Peter
Wu, Tianxia
Bielekova, Bibiana
author_sort Stein, Jason
collection PubMed
description Although B cell depletion is an effective therapy of multiple sclerosis (MS), the pathogenic functions of B cells in MS remain incompletely understood. We asked whether cerebrospinal fluid (CSF) B cells in MS secrete different cytokines than control-subject B cells and whether cytokine secretion affects MS phenotype. We blindly studied CSF B cells after their immortalization by Epstein-Barr Virus (EBV) in prospectively-collected MS patients and control subjects with other inflammatory-(OIND) or non-inflammatory neurological diseases (NIND) and healthy volunteers (HV). The pilot cohort (n = 80) was analyzed using intracellular cytokine staining (n = 101 B cell lines [BCL] derived from 35 out of 80 subjects). We validated differences in cytokine production in newly-generated CSF BCL (n = 207 BCL derived from subsequent 112 prospectively-recruited subjects representing validation cohort), using ELISA enhanced by objective, flow-cytometry-based B cell counting. After unblinding the pilot cohort, the immortalization efficiency was almost 5 times higher in MS patients compared to controls (p < 0.001). MS subjects' BCLs produced significantly more vascular endothelial growth factor (VEGF) compared to control BCLs. Progressive MS patients BCLs produced significantly more tumor necrosis factor (TNF)-α and lymphotoxin (LT)-α than BCL from relapsing-remitting MS (RRMS) patients. In the validation cohort, we observed lower secretion of IL-1β in RRMS patients, compared to all other diagnostic categories. The validation cohort validated enhanced VEGF-C production by BCL from RRMS patients and higher TNF-α and LT-α secretion by BCL from progressive MS. No significant differences among diagnostic categories were observed in secretion of IL-6 or GM-CSF. However, B cell secretion of IL-1β, TNF-α, and GM-CSF correlated significantly with the rate of accumulation of disability measured by MS disease severity scale (MS-DSS). Finally, all three cytokines with increased secretion in different stages of MS (i.e., VEGF-C, TNF-α, and LT-α) enhance lymphangiogenesis, suggesting that intrathecal B cells directly facilitate the formation of tertiary lymphoid follicles, thus compartmentalizing inflammation to the central nervous system.
format Online
Article
Text
id pubmed-6062589
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60625892018-08-03 Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects Stein, Jason Xu, Quangang Jackson, Kayla C. Romm, Elena Wuest, Simone C. Kosa, Peter Wu, Tianxia Bielekova, Bibiana Front Neurol Neurology Although B cell depletion is an effective therapy of multiple sclerosis (MS), the pathogenic functions of B cells in MS remain incompletely understood. We asked whether cerebrospinal fluid (CSF) B cells in MS secrete different cytokines than control-subject B cells and whether cytokine secretion affects MS phenotype. We blindly studied CSF B cells after their immortalization by Epstein-Barr Virus (EBV) in prospectively-collected MS patients and control subjects with other inflammatory-(OIND) or non-inflammatory neurological diseases (NIND) and healthy volunteers (HV). The pilot cohort (n = 80) was analyzed using intracellular cytokine staining (n = 101 B cell lines [BCL] derived from 35 out of 80 subjects). We validated differences in cytokine production in newly-generated CSF BCL (n = 207 BCL derived from subsequent 112 prospectively-recruited subjects representing validation cohort), using ELISA enhanced by objective, flow-cytometry-based B cell counting. After unblinding the pilot cohort, the immortalization efficiency was almost 5 times higher in MS patients compared to controls (p < 0.001). MS subjects' BCLs produced significantly more vascular endothelial growth factor (VEGF) compared to control BCLs. Progressive MS patients BCLs produced significantly more tumor necrosis factor (TNF)-α and lymphotoxin (LT)-α than BCL from relapsing-remitting MS (RRMS) patients. In the validation cohort, we observed lower secretion of IL-1β in RRMS patients, compared to all other diagnostic categories. The validation cohort validated enhanced VEGF-C production by BCL from RRMS patients and higher TNF-α and LT-α secretion by BCL from progressive MS. No significant differences among diagnostic categories were observed in secretion of IL-6 or GM-CSF. However, B cell secretion of IL-1β, TNF-α, and GM-CSF correlated significantly with the rate of accumulation of disability measured by MS disease severity scale (MS-DSS). Finally, all three cytokines with increased secretion in different stages of MS (i.e., VEGF-C, TNF-α, and LT-α) enhance lymphangiogenesis, suggesting that intrathecal B cells directly facilitate the formation of tertiary lymphoid follicles, thus compartmentalizing inflammation to the central nervous system. Frontiers Media S.A. 2018-07-20 /pmc/articles/PMC6062589/ /pubmed/30079049 http://dx.doi.org/10.3389/fneur.2018.00554 Text en Copyright © 2018 Stein, Xu, Jackson, Romm, Wuest, Kosa, Wu and Bielekova. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Stein, Jason
Xu, Quangang
Jackson, Kayla C.
Romm, Elena
Wuest, Simone C.
Kosa, Peter
Wu, Tianxia
Bielekova, Bibiana
Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title_full Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title_fullStr Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title_full_unstemmed Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title_short Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
title_sort intrathecal b cells in ms have significantly greater lymphangiogenic potential compared to b cells derived from non-ms subjects
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062589/
https://www.ncbi.nlm.nih.gov/pubmed/30079049
http://dx.doi.org/10.3389/fneur.2018.00554
work_keys_str_mv AT steinjason intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT xuquangang intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT jacksonkaylac intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT rommelena intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT wuestsimonec intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT kosapeter intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT wutianxia intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects
AT bielekovabibiana intrathecalbcellsinmshavesignificantlygreaterlymphangiogenicpotentialcomparedtobcellsderivedfromnonmssubjects